USA flag logo/image

An Official Website of the United States Government

Retinoids as Novel Treatment of Ischemic Stroke

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
80419
Program Year/Program:
2006 / STTR
Agency Tracking Number:
NS053041
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ACRYMED, INC.
ACRYMED, INC. 9560 SW Nimbus Ave. BEAVERTON, OR 97008
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2006
Title: Retinoids as Novel Treatment of Ischemic Stroke
Agency: HHS
Contract: 1R41NS053041-01A1
Award Amount: $130,453.00
 

Abstract:

DESCRIPTION (provided by applicant): Stroke is the third leading cause of death in the U.S. and a major source of disability. Ischemic stroke, the most common type, is associated with a dramatic increase in calcium influx in brain tissue, an increased production in reactive oxygen species (ROS), cell death and inflammation. Studies by the PI have shown that retinoids block neuronal voltage-gated calcium channels. Studies by others suggest that retinoids reduce tissue levels of reactive oxygen species and prevents cellular apoptosis, increase tissue plasminogen activator, favorably modify the balance of pro-inflammatory and inflammatory cytokines and attenuate inflammation in vivo. Together, the data suggest that retinoids might be neuroprotective and potentially useful in the treatment of ischemic stroke. Our goal is to demonstrate that retinoids have neuroprotective activity in vivo. Specifically, we propose to demonstrate that treatment with retinoids: 1) attenuates post-stroke motor deficits using a mouse model of permanent focal cerebral ischemia (middle cerebral artery occlusion), 2) reduces cerebral infarct size, and 3) reduces the expression of the biochemical markers of apoptosis, ROS production and inflammation in the ischemic brain. The project will provide a rationale for the development of retinoid-based formulations to treat ischemic stroke and for the screening of retinoid libraries in search of more potent compounds.

Principal Investigator:

Jeanbaptiste O. Roullet
5034944979
ROULLETJ@OHSU.EDU

Business Contact:


5036249830
Small Business Information at Submission:

ACRYMED, INC.
ACRYMED, INC. 9560 SW Nimbus Ave. BEAVERTON, OR 97008

EIN/Tax ID: 931134143
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
OREGON HEALTH & SCIENCE UNIVERSITY
OREGON HEALTH & SCIENCE UNIVERSITY
3181 SW Sam Jackson Pk Rd
PORTLAND, OR 97239
RI Type: Nonprofit college or university